Showing posts with label ADHD. Show all posts
Showing posts with label ADHD. Show all posts

Sunday, February 16, 2014

Rare genetic mutation confirmed as a cause of Tourette Syndrome

Brain researchers say they have confirmed for the first time that a rare genetic mutation can cause some cases of Tourette syndrome, with the fault disrupting production of histamine in the brain.
The New Haven, CT, researchers at the Yale School of Medicine say the histamine effect "is a cause of the tics and other abnormalities of Tourette syndrome." Tics are repetitive movements and vocal sounds, and they are unwanted and involuntary - they cannot be controlled.
Publishing their research on mice in the journal Neuron, the authors raise the question of investigating treatment of Tourette syndrome by drugs that target histamine receptors in the brain.
Drugs with such a mode of action are already being explored by pharmaceutical companies for the treatment of separate brain disorders, schizophrenia and ADHD.
Information from the national gene database about histamine describes the chemical's role - it is a messenger molecule released by nerves, among other functions.
Current neurological drugs under investigation target a certain gene-encoded histamine receptor known as the histamine H3 receptor.
Christopher Pittenger, of the Yale Child Study Center and associate professor of psychiatry and psychology, says of his particular study on histamine genetics:
"These findings give us a new window into what's going on in the brain in people with Tourette. That's likely to lead us to new treatments."
Histamine also has an important role in inflammation, which is why antihistamines work to reduce allergy symptoms. Interactions with the histamine system in the brain, say the Yale researchers, "explain why some allergy medications cause people to feel sleepy."
The specific gene in this study is called HDC (the histidine decarboxylase gene), which the researchers previously found to be mutated in a family that had nine members with Tourette syndrome.
Mouse with glass containers
Researchers found that mice with a faulty HDC gene showed symptoms similar to those found in Tourette syndrome.
That earlier finding of a faulty gene led the authors to confirm its effects on histamine in their present study with mice.
Mice with the same mutation carried by the Tourette family developed symptoms similar to those found in the syndrome, the Yale team showed, saying that this helps to prove that the histamine disruption can cause the tics.

Brain structures and chemicals

The study also found effects to do with dopamine, another brain chemical involved in communication between nerve cells.
There were abnormalities in dopamine neurotransmitter signaling in mice and in the patients carrying the faulty HDC gene.
The disruption was to dopamine effects in the basal ganglia, which is a network of structures responsible for movement - and the part of the brain that Dr. Pittenger focuses on toward the scientific understanding of neuropsychiatric diseases.
His research biography says:
"The basal ganglia are involved both in motor control and in the formation of habits.
Abnormalities in this circuit are implicated in a variety of conditions characterized by maladaptive, inflexible behaviors - habits gone bad.
These include obsessive-compulsive disorder, Tourette syndrome, and drug addiction."
The Tourette Syndrome Association of America - a non-profit whose mission "is to identify the cause of, find the cure for, and control the effects of Tourette Syndrome" - helped to fund the Yale study, which also received financial support from the Allison Family Foundation and the National Institutes of Health.
The US Centers for Disease Control and Prevention (CDC) does not have a firm estimate of the number of people affected by Tourette syndrome in America, but has run studies that indicate a prevalence of between 3 and 6 children out of every 1,000 in the population.
Other researchers, from the Massachusetts General Hospital and the University of Chicago, have also found family genetics behind Tourette's - and obsessive compulsive disorder (OCD), too. Their PLOS Genetics study published in October 2013 found insights into genetic architecture.

Friday, February 14, 2014

New approach for those with Tourette Syndrome being tested in clinical trials


Medical researchers are hopeful that a new investigational drug being tested in clinical trials will prove to be an effective treatment for Tourette Syndrome – an inherited, misdiagnosed, misunderstood neurological disorder that presents in childhood and causes involuntary motor and vocal tics.
The new drug, AZD5213, targets the human histamine H3 receptor.  In the brain, this receptor regulates neurotransmitters associated with Tourette Syndrome – including dopamine and histamine.A mutation that affects histamine synthesis was recently confirmed to be the cause of TS in a father and all eight of his children, a finding supported by research in mice.
If approved for treatment of Tourette, AZD5213 might represent an alternative to antipsychotics, which don’t work well in all patients and can cause serious negative side effects.  Discovered by AstraZeneca, AZD5213 has been shown to have a favorable safety profile, with no serious drug-related side effects reported in Phase 1 and Phase 2 clinical trials completed at the time of this report.
“AZD5213 represents an exciting new approach to the treatment of Tourette Syndrome, and we are currently recruiting teenagers suffering from the disorder to participate in the clinical trial,” says Dr. Roger Kurlan, Director of the Movement Disorders Program at Overlook Medical Center’s Atlantic Neuroscience Institute in Summit, N.J.
Dr. Kurlan, who frequently collaborates with the NJ Center for Tourette Syndrome & Associated Disorders (NJCTS) in Somerville, N.J., is a leading expert in the treatment of Tourette and is one of approximately six medical researchers involved in the clinical trial.
AZD5213 already has been studied in other clinical trials, including those for Alzheimer’s disease. With Tourette Syndrome, which is associated with changes in brain chemistry that appear to cause the characteristic symptoms of the disorder, AZD5213 might be able to counteract these changes – with the potential to provide symptomatic relief with less of the negative side effects associated with existing treatments.  More than 200 human subjects have already received single or multiple doses of AZD5213, with no serious drug-related adverse side effects.
The clinical trial is a 6-month, multicenter, randomized, safety, tolerability, pharmacokinetic, and preliminary efficacy study of AZD5213 in adolescents 12 to 17 years of age with Tourette Syndrome. The trial includes an up to 21-day screening period, 6 months of once-daily treatment with placebo or AZD5213, and a 3-week follow-up period.
Because of the crossover design of the trial, all enrolled patients will receive AZD5213 for at least part of the trial. Approximately 24 subjects will be treated in this study.  Safety will be carefully ensured by a battery of safety tests administered at visits throughout the study, and efficacy will be determined by means of questionnaires designed to assess the severity of symptoms associated with Tourette Syndrome.
According to the Centers for Disease Control and Prevention (CDC), 1 in 100 children show signs of Tourette Syndrome. The disorder is three times as likely in boys as in girls, and most patients experience their worst symptoms in their early teen years. There is no cure, and symptoms can persist throughout life – although most patients see improvement as they approach and enter adulthood.
Exaggerated portrayals of Tourette Syndrome have been used for comic relief in films and TV shows, usually featuring characters who shout obscenities involuntarily. In reality, this type of verbal tic – known as coprolalia – is present in only 10 to 15 percent of those with TS.
“In real life, Tourette’s is no laughing matter,” Dr. Kurlan says. “These patients often struggle with self-esteem and socialization issues, which generally arise at a crucial time in their social development. Sadly, many are victims of bullying and the ridicule of their peers.”
Tourette’s is most often present in combination with other neurological disorders, such as attention deficit-hyperactivity disorder (ADHD) or obsessive-compulsive disorder (OCD), and Tourette’s patients are commonly troubled by depression, anxiety and developmental delays.

This post brought to you in part by republicwireless.com

Friday, January 31, 2014

Asperger's Comorbid Conditions


Depression is Common Among Those with Asperger's.
Depression is Common Among Those with Asperger's.|stock.xchng http://www.sxc.hu/

Asperger’s Syndrome (AS), one of the five conditions found on the autism spectrum, is a developmental disorder that mainly affects a person’s social communication. There are certain comorbid conditions that are found quite frequently among individuals with Asperger’s Syndrome. These conditions do not need to be present in order to receive a diagnosis of Asperger’s Syndrome, but one or more is usually found alongside the AS diagnosis.

Sensory Processing Disorder (SPD)

Although not officially a diagnostic category in the Diagnostic and Statistics Manual of Mental Disorders (DSM), sensory processing disorder is widespread among all individuals on the autism spectrum, including those with Asperger’s Syndrome. Individuals with AS are usually over-responsive to sensory stimuli; loud noises, scratchy clothing, and unusual textures all serve as sources of irritation among those with AS.

Attention-Deficit Hyperactivity Disorder (ADHD)

According to an article published on Medscape, one study of children with Asperger’s Syndrome showed that 62.5% of the participants also showed clinical symptoms indicating attention-deficit hyperactivity disorder (ADHD).

Anxiety

Anxiety is extremely common among individuals with Asperger’s Syndrome. According to Tony Attwood, “We know that more people with autism spectrum disorder (ASD, e.g. Asperger’s syndrome, autism) experience anxiety and depression than people who do not have ASD.” Anxiety can take the form of obsessive-compulsive disorder, specific fears and phobias, and generalized anxieties.

Depression

According to an SMHAI study, approximately 1 in 15 individuals with Asperger’s Syndrome also meet the diagnostic criteria for depression. It is unknown exactly what causes the depression but it is likely that it is a combination between the individual’s realization of their difference from their peers and the ostracizing that occurs from these peers. Bullying is an extremely common problem among individuals with AS; this bullying could very likely lead to an increased rate of depression among the AS population.

Dyspraxia

Sometimes called motor-planning disorder, dyspraxia is seen in a large majority of individuals with Asperger’s Syndrome. In fact motor clumsiness is so common that one diagnostic model for Asperger’s Syndrome, Gillberg’s Criteria for Asperger’s Disorder, includes motor clumsiness as a symptom which must be present in order for an individual to receive an AS diagnosis.

Tourette’s Syndrome

Although not seen as commonly as ADHD and anxiety disorders, it is not unusual to see individuals with Tourette’s syndrome as well as Asperger’s Syndrome. Tourette’s syndrome is characterized by repetitive vocal and motor tics.
These six conditions exist in the general public and in the absence of Asperger’s Syndrome. However, the rate of diagnosis among individuals with AS is unusually high when compared with those not on the spectrum. In time, scientists hope to better understand the link between these conditions.

Tuesday, April 23, 2013

Mayor Asks City Attorney to Research Marijuana Decriminalization


Lansing Mayor Virg Bernero is asking the city attorney to look into the impact and legalities of decriminalizing marijuana. He told wilx.com it's just a matter of time until there's a referendum on the issue, so he wants to know how cities like Grand Rapids and Kalamazoo have implemented it and how they're complying with state law.
 "It's there, it's available in our community. I think we're better off dealing with it as a civil infraction and dealing with the reality of it."
The Mayor doesn't think decriminalization would be a huge change in Lansing because police don't treat simple possession as a priority right now. "We don't have the manpower to go after individual cases, so turning it into a civil infraction in many ways is just recognizing what already is, but would also stop the criminalization of a lot of our young people."
Decriminalization means people caught with marijuana, assuming they aren't complying with the state's medical marijuana law, would be given a ticket instead of being arrested. The Mayor calls it a rational approach to a drug that's readily available in the community. In fact, he says it's been pushed into neighborhoods since the state asked the courts to ban medical marijuana dispensaries.
The Mayor thinks a referendum would be the best way to decide if Lansing should decriminalize marijuana, but he won't be leading the charge for it and he isn't supporting legalization.

Read More
Grow Cannabis Indoors

Thursday, April 18, 2013

Tourette’s Syndrome: Comorbid Disorders


Tourette Syndrome (TS) often occurs with other related conditions (also called co-occurring conditions). These conditions can include:
 attention-deficit/hyperactivity disorder (ADHD) obsessive-compulsive disorder (OCD)
Mood disorders such as depression and Bipolar Disorder and other behavioral or conduct problems,
  and n
on-OCD anxiety disorders
People with TS and related conditions can be at higher risk for learning, behavioral, and social problems.
The symptoms of other disorders can complicate the diagnosis and treatment of TS and create extra challenges for people with TS and their families, educators, and health professionals.
Findings from a national Centers for Disease Control and Prevention (CDC) study1 indicated that 79% of children who had been diagnosed with TS also had been diagnosed with at least one additional mental health, behavioral, or developmental condition based on parent report.


Among children with TS:
64% had ADHD.
43% had behavioral problems, such as oppositional defiant disorder (ODD) or conduct disorder (CD).
40% had anxiety problems.
36% had depression.
28% had a developmental delay

Because co-occurring conditions are so common among people with TS, it is important for doctors to assess every child with TS for other conditions and problems.






Pages